Analysts See Pick Up in 2H Orders at Mako Surgical (MAKO)
Tweet
Share
E-mailGet Alerts MAKO Hot Sheet
Price: $29.99 --0%
Rating Summary:
1 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 14 | New: 17
Rating Summary:
1 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 14 | New: 17
Join SI Premium – FREE
Mako (Nasdaq: MAKO) shares have started to bounce off recent lows, as investors gain confidence in the stabilization of the business and a potential pick-up in orders in second half of the year, noted a recent report from analysts at JPMorgan.
Mako’s Rio Robotic system is an interesting and potentially platform technology in orthopedics. The company launched its latest application for Rio in September 2011. Initial interest in the Rio hip application has been modest, but analysts are optimistic that the company could ultimately find its next leg of growth in hip surgery.
JPM channel checks suggest that the company will at least hit its third quarter system numbers based on hospital checks, which bodes well for the company.
“The next catalyst for the shares should be the presentation of alignment data by Dr. Henrik Malchau of Mass General Hospital in Boston October 3rd,” thinks analyst Kimberly Gailun.
“Harvard Medical School will be hosting its 42nd Annual Advances in Arthroplasty course in Cambridge, MA, from October 2-5th, and Dr. Malchau is expected to present on 'Precise Placement of Implants Using Robotic Technology' late Wednesday afternoon. We see the potential for this data (if positive) to help support the viability of Mako's hip application.”
JPMorgan recently increase their price target on Mako to $20.00 (from $17). The bank has a Neutral rating on the stock.
For an analyst ratings summary and ratings history on MAKO Surgical click here. For more ratings news on MAKO Surgical click here.
Shares of MAKO Surgical closed at $18.81 yesterday.
Mako’s Rio Robotic system is an interesting and potentially platform technology in orthopedics. The company launched its latest application for Rio in September 2011. Initial interest in the Rio hip application has been modest, but analysts are optimistic that the company could ultimately find its next leg of growth in hip surgery.
JPM channel checks suggest that the company will at least hit its third quarter system numbers based on hospital checks, which bodes well for the company.
“The next catalyst for the shares should be the presentation of alignment data by Dr. Henrik Malchau of Mass General Hospital in Boston October 3rd,” thinks analyst Kimberly Gailun.
“Harvard Medical School will be hosting its 42nd Annual Advances in Arthroplasty course in Cambridge, MA, from October 2-5th, and Dr. Malchau is expected to present on 'Precise Placement of Implants Using Robotic Technology' late Wednesday afternoon. We see the potential for this data (if positive) to help support the viability of Mako's hip application.”
JPMorgan recently increase their price target on Mako to $20.00 (from $17). The bank has a Neutral rating on the stock.
For an analyst ratings summary and ratings history on MAKO Surgical click here. For more ratings news on MAKO Surgical click here.
Shares of MAKO Surgical closed at $18.81 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rentokil Initial (RTO) PT Lowered to $35 at Oppenheimer
- Badger Meter (BMI) PT Raised to $175 at Stifel
- Orora Ltd. (ORA:AU) (ORRAF) PT Lowered to AUD2.20 at JPMorgan
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
